Skip to main content
Erschienen in: Clinical and Experimental Nephrology 1/2012

01.02.2012 | Review Article

The roles of V1a vasopressin receptors in blood pressure homeostasis: a review of studies on V1a receptor knockout mice

verfasst von: Yoko Fujiwara, Akito Tanoue, Gozoh Tsujimoto, Taka-aki Koshimizu

Erschienen in: Clinical and Experimental Nephrology | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

A prompt rise in blood pressure occurs when arginine-vasopressin is administered in quantities adequate to activate vascular V1a subtype vasopressin receptors. However, it has been controversial whether the endogenous vasopressin-V1a system contributes to the maintenance of basal blood pressure during normal development and aging. Mutant mice lacking the V1a receptor gene (V1a−/−) show significantly lower blood pressure compared to control mice, without a notable change in heart rate. In V1a−/− mice, arterial baroreceptor reflexes were attenuated due to malfunctioning baroreflex center, and the mice’s circulating blood volume was significantly reduced. In line with this reduction in circulating blood volume, adrenocortical hormone release was attenuated; plasma aldosterone levels were reduced and adrenocorticotropic hormone-stimulated corticosteroid release was attenuated. In addition, V1a receptor expression was detected in macula densa cells of the kidneys, which may have facilitated renin production from the juxtaglomerular cells. Deletion of the V1a receptor appears to impact the renin–angiotensin–aldosterone system. Studies on V1a−/− mice revealed that non-vascular V1a receptors in the central nervous system and peripheral tissues play critical roles in the maintenance of blood pressure homeostasis.
Literatur
1.
Zurück zum Zitat Kovacs GL, Bohus B, Versteeg DH, de Kloet ER, de Wied D. Effect of oxytocin and vasopressin on memory consolidation: sites of action and catecholaminergic correlates after local microinjection into limbic-midbrain structures. Brain Res. 1979;175(2):303–14.PubMedCrossRef Kovacs GL, Bohus B, Versteeg DH, de Kloet ER, de Wied D. Effect of oxytocin and vasopressin on memory consolidation: sites of action and catecholaminergic correlates after local microinjection into limbic-midbrain structures. Brain Res. 1979;175(2):303–14.PubMedCrossRef
2.
Zurück zum Zitat Kribben A, Wieder ED, Li X, van Putten V, Granot Y, Schrier RW, Nemenoff RA. AVP-induced activation of MAP kinase in vascular smooth muscle cells is mediated through protein kinase C. Am J Physiol. 1993;265(4 Pt 1):C939–45.PubMed Kribben A, Wieder ED, Li X, van Putten V, Granot Y, Schrier RW, Nemenoff RA. AVP-induced activation of MAP kinase in vascular smooth muscle cells is mediated through protein kinase C. Am J Physiol. 1993;265(4 Pt 1):C939–45.PubMed
3.
Zurück zum Zitat Rivier C, Vale W. Modulation of stress-induced ACTH release by corticotropin-releasing factor, catecholamines and vasopressin. Nature. 1983;305(5932):325–7.PubMedCrossRef Rivier C, Vale W. Modulation of stress-induced ACTH release by corticotropin-releasing factor, catecholamines and vasopressin. Nature. 1983;305(5932):325–7.PubMedCrossRef
4.
Zurück zum Zitat Hems DA, Whitton PD. Stimulation by vasopressin of glycogen breakdown and gluconeogenesis in the perfused rat liver. Biochem J. 1973;136(3):705–9.PubMed Hems DA, Whitton PD. Stimulation by vasopressin of glycogen breakdown and gluconeogenesis in the perfused rat liver. Biochem J. 1973;136(3):705–9.PubMed
5.
Zurück zum Zitat Nielsen S, DiGiovanni SR, Christensen EI, Knepper MA, Harris HW. Cellular and subcellular immunolocalization of vasopressin-regulated water channel in rat kidney. Proc Natl Acad Sci USA. 1993;90(24):11663–7.PubMedCrossRef Nielsen S, DiGiovanni SR, Christensen EI, Knepper MA, Harris HW. Cellular and subcellular immunolocalization of vasopressin-regulated water channel in rat kidney. Proc Natl Acad Sci USA. 1993;90(24):11663–7.PubMedCrossRef
6.
Zurück zum Zitat Johnston CI. Vasopressin in circulatory control and hypertension. J Hypertens. 1985;3(6):557–69.PubMedCrossRef Johnston CI. Vasopressin in circulatory control and hypertension. J Hypertens. 1985;3(6):557–69.PubMedCrossRef
7.
Zurück zum Zitat Thibonnier M, Coles P, Thibonnier A, Shoham M. Molecular pharmacology and modeling of vasopressin receptors. Prog Brain Res. 2002;139:179–96.PubMedCrossRef Thibonnier M, Coles P, Thibonnier A, Shoham M. Molecular pharmacology and modeling of vasopressin receptors. Prog Brain Res. 2002;139:179–96.PubMedCrossRef
8.
Zurück zum Zitat Ali F, Guglin M, Vaitkevicius P, Ghali JK. Therapeutic potential of vasopressin receptor antagonists. Drugs. 2007;67(6):847–58.PubMedCrossRef Ali F, Guglin M, Vaitkevicius P, Ghali JK. Therapeutic potential of vasopressin receptor antagonists. Drugs. 2007;67(6):847–58.PubMedCrossRef
9.
Zurück zum Zitat Share L. Role of vasopressin in cardiovascular regulation. Physiol Rev. 1988;68(4):1248–84.PubMed Share L. Role of vasopressin in cardiovascular regulation. Physiol Rev. 1988;68(4):1248–84.PubMed
10.
Zurück zum Zitat Liard JF. Vasopressin in cardiovascular control: role of circulating vasopressin. Clin Sci (Lond). 1984;67(5):473–81. Liard JF. Vasopressin in cardiovascular control: role of circulating vasopressin. Clin Sci (Lond). 1984;67(5):473–81.
11.
Zurück zum Zitat Erlenbach I, Wess J. Molecular basis of V2 vasopressin receptor/Gs coupling selectivity. J Biol Chem. 1998;273(41):26549–58.PubMedCrossRef Erlenbach I, Wess J. Molecular basis of V2 vasopressin receptor/Gs coupling selectivity. J Biol Chem. 1998;273(41):26549–58.PubMedCrossRef
12.
Zurück zum Zitat Ostrowski NL, Young WS 3rd, Knepper MA, Lolait SJ. Expression of vasopressin V1a and V2 receptor messenger ribonucleic acid in the liver and kidney of embryonic, developing, and adult rats. Endocrinology. 1993;133(4):1849–59.PubMedCrossRef Ostrowski NL, Young WS 3rd, Knepper MA, Lolait SJ. Expression of vasopressin V1a and V2 receptor messenger ribonucleic acid in the liver and kidney of embryonic, developing, and adult rats. Endocrinology. 1993;133(4):1849–59.PubMedCrossRef
13.
Zurück zum Zitat Klussmann E, Maric K, Wiesner B, Beyermann M, Rosenthal W. Protein kinase A anchoring proteins are required for vasopressin-mediated translocation of aquaporin-2 into cell membranes of renal principal cells. J Biol Chem. 1999;274(8):4934–8.PubMedCrossRef Klussmann E, Maric K, Wiesner B, Beyermann M, Rosenthal W. Protein kinase A anchoring proteins are required for vasopressin-mediated translocation of aquaporin-2 into cell membranes of renal principal cells. J Biol Chem. 1999;274(8):4934–8.PubMedCrossRef
14.
Zurück zum Zitat Burrell LM, Phillips PA, Risvanis J, Aldred KL, Hutchins AM, Johnston CI. Attenuation of genetic hypertension after short-term vasopressin V1A receptor antagonism. Hypertension. 1995;26(5):828–34.PubMed Burrell LM, Phillips PA, Risvanis J, Aldred KL, Hutchins AM, Johnston CI. Attenuation of genetic hypertension after short-term vasopressin V1A receptor antagonism. Hypertension. 1995;26(5):828–34.PubMed
15.
Zurück zum Zitat Burrell LM, Phillips PA, Stephenson JM, Risvanis J, Rolls KA, Johnston CI. Blood pressure-lowering effect of an orally active vasopressin V1 receptor antagonist in mineralocorticoid hypertension in the rat. Hypertension. 1994;23(6 Pt 1):737–43.PubMed Burrell LM, Phillips PA, Stephenson JM, Risvanis J, Rolls KA, Johnston CI. Blood pressure-lowering effect of an orally active vasopressin V1 receptor antagonist in mineralocorticoid hypertension in the rat. Hypertension. 1994;23(6 Pt 1):737–43.PubMed
16.
Zurück zum Zitat Jackson EK. Vasopressin and other agents affecting the renal conservation of water. In: Hardman JG, Limbird LE, Goodman Gilman A, editors. Goodman & Gilman’s the pharmacological basis of therapeutics. MacGraw-Hill: New York; 1996. p. 715–31. Jackson EK. Vasopressin and other agents affecting the renal conservation of water. In: Hardman JG, Limbird LE, Goodman Gilman A, editors. Goodman & Gilman’s the pharmacological basis of therapeutics. MacGraw-Hill: New York; 1996. p. 715–31.
17.
Zurück zum Zitat Yamamura Y, Ogawa H, Chihara T, Kondo K, Onogawa T, Nakamura S, Mori T, Tominaga M, Yabuuchi Y. OPC-21268, an orally effective, nonpeptide vasopressin V1 receptor antagonist. Science. 1991;252(5005):572–4.PubMedCrossRef Yamamura Y, Ogawa H, Chihara T, Kondo K, Onogawa T, Nakamura S, Mori T, Tominaga M, Yabuuchi Y. OPC-21268, an orally effective, nonpeptide vasopressin V1 receptor antagonist. Science. 1991;252(5005):572–4.PubMedCrossRef
18.
Zurück zum Zitat Serradeil-Le Gal C, Wagnon J, Garcia C, Lacour C, Guiraudou P, Christophe B, Villanova G, Nisato D, Maffrand JP, Le Fur G, et al. Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V1a receptors. J Clin Invest. 1993;92(1):224–31. Serradeil-Le Gal C, Wagnon J, Garcia C, Lacour C, Guiraudou P, Christophe B, Villanova G, Nisato D, Maffrand JP, Le Fur G, et al. Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V1a receptors. J Clin Invest. 1993;92(1):224–31.
19.
Zurück zum Zitat Chapman JT, Hreash F, Laycock JF, Walter SJ. The cardiovascular effects of vasopressin after haemorrhage in anaesthetized rats. J Physiol. 1986;375:421–34.PubMed Chapman JT, Hreash F, Laycock JF, Walter SJ. The cardiovascular effects of vasopressin after haemorrhage in anaesthetized rats. J Physiol. 1986;375:421–34.PubMed
20.
Zurück zum Zitat Sladek CD, Blair ML, Sterling C, Mangiapane ML. Attenuation of spontaneous hypertension in rats by a vasopressin antagonist. Hypertension. 1988;12(5):506–12.PubMed Sladek CD, Blair ML, Sterling C, Mangiapane ML. Attenuation of spontaneous hypertension in rats by a vasopressin antagonist. Hypertension. 1988;12(5):506–12.PubMed
21.
Zurück zum Zitat Valtin H. The discovery of the Brattleboro rat, recommended nomenclature, and the question of proper controls. Ann N Y Acad Sci. 1982;394:1–9.PubMedCrossRef Valtin H. The discovery of the Brattleboro rat, recommended nomenclature, and the question of proper controls. Ann N Y Acad Sci. 1982;394:1–9.PubMedCrossRef
22.
Zurück zum Zitat Padfield PL, Brown JJ, Lever AF, Morton JJ, Robertson JI. Blood pressure in acute and chronic vasopressin excess: studies of malignant hypertension and the syndrome of inappropriate antidiuretic hormone secretion. N Engl J Med. 1981;304(18):1067–70.PubMedCrossRef Padfield PL, Brown JJ, Lever AF, Morton JJ, Robertson JI. Blood pressure in acute and chronic vasopressin excess: studies of malignant hypertension and the syndrome of inappropriate antidiuretic hormone secretion. N Engl J Med. 1981;304(18):1067–70.PubMedCrossRef
23.
Zurück zum Zitat Koshimizu TA, Nasa Y, Tanoue A, Oikawa R, Kawahara Y, Kiyono Y, Adachi T, Tanaka T, Kuwaki T, Mori T, Takeo S, Okamura H, Tsujimoto G. V1a vasopressin receptors maintain normal blood pressure by regulating circulating blood volume and baroreflex sensitivity. Proc Natl Acad Sci USA. 2006;103(20):7807–12.PubMedCrossRef Koshimizu TA, Nasa Y, Tanoue A, Oikawa R, Kawahara Y, Kiyono Y, Adachi T, Tanaka T, Kuwaki T, Mori T, Takeo S, Okamura H, Tsujimoto G. V1a vasopressin receptors maintain normal blood pressure by regulating circulating blood volume and baroreflex sensitivity. Proc Natl Acad Sci USA. 2006;103(20):7807–12.PubMedCrossRef
24.
Zurück zum Zitat Braunwald E, Wagner HN Jr. The pressor effect of the antidiuretic principle of the posterior pituitary in orthostatic hypotension. J Clin Invest. 1956;35(12):1412–8.PubMedCrossRef Braunwald E, Wagner HN Jr. The pressor effect of the antidiuretic principle of the posterior pituitary in orthostatic hypotension. J Clin Invest. 1956;35(12):1412–8.PubMedCrossRef
25.
Zurück zum Zitat Aoyagi T, Birumachi J, Hiroyama M, Fujiwara Y, Sanbe A, Yamauchi J, Tanoue A. Alteration of glucose homeostasis in V1a vasopressin receptor-deficient mice. Endocrinology. 2007;148(5):2075–84.PubMedCrossRef Aoyagi T, Birumachi J, Hiroyama M, Fujiwara Y, Sanbe A, Yamauchi J, Tanoue A. Alteration of glucose homeostasis in V1a vasopressin receptor-deficient mice. Endocrinology. 2007;148(5):2075–84.PubMedCrossRef
26.
Zurück zum Zitat Aoyagi T, Izumi Y, Hiroyama M, Matsuzaki T, Yasuoka Y, Sanbe A, Miyazaki H, Fujiwara Y, Nakayama Y, Kohda Y, Yamauchi J, Inoue T, Kawahara K, Saito H, Tomita K, Nonoguchi H, Tanoue A. Vasopressin regulates the renin–angiotensin–aldosterone system via V1a receptors in macula densa cells. Am J Physiol Renal Physiol. 2008;295(1):F100–7.PubMedCrossRef Aoyagi T, Izumi Y, Hiroyama M, Matsuzaki T, Yasuoka Y, Sanbe A, Miyazaki H, Fujiwara Y, Nakayama Y, Kohda Y, Yamauchi J, Inoue T, Kawahara K, Saito H, Tomita K, Nonoguchi H, Tanoue A. Vasopressin regulates the renin–angiotensin–aldosterone system via V1a receptors in macula densa cells. Am J Physiol Renal Physiol. 2008;295(1):F100–7.PubMedCrossRef
27.
Zurück zum Zitat Guillon G, Trueba M, Joubert D, Grazzini E, Chouinard L, Cote M, Payet MD, Manzoni O, Barberis C, Robert M, et al. Vasopressin stimulates steroid secretion in human adrenal glands: comparison with angiotensin-II effect. Endocrinology. 1995;136(3):1285–95. Guillon G, Trueba M, Joubert D, Grazzini E, Chouinard L, Cote M, Payet MD, Manzoni O, Barberis C, Robert M, et al. Vasopressin stimulates steroid secretion in human adrenal glands: comparison with angiotensin-II effect. Endocrinology. 1995;136(3):1285–95.
28.
Zurück zum Zitat Perraudin V, Delarue C, Lefebvre H, Do Rego JL, Vaudry H, Kuhn JM. Evidence for a role of vasopressin in the control of aldosterone secretion in primary aldosteronism: in vitro and in vivo studies. J Clin Endocrinol Metab. 2006;91(4):1566–72.PubMedCrossRef Perraudin V, Delarue C, Lefebvre H, Do Rego JL, Vaudry H, Kuhn JM. Evidence for a role of vasopressin in the control of aldosterone secretion in primary aldosteronism: in vitro and in vivo studies. J Clin Endocrinol Metab. 2006;91(4):1566–72.PubMedCrossRef
29.
Zurück zum Zitat Birumachi J, Hiroyama M, Fujiwara Y, Aoyagi T, Sanbe A, Tanoue A. Impaired arginine-vasopressin-induced aldosterone release from adrenal gland cells in mice lacking the vasopressin V1A receptor. Eur J Pharmacol. 2007;566(1–3):226–30.PubMedCrossRef Birumachi J, Hiroyama M, Fujiwara Y, Aoyagi T, Sanbe A, Tanoue A. Impaired arginine-vasopressin-induced aldosterone release from adrenal gland cells in mice lacking the vasopressin V1A receptor. Eur J Pharmacol. 2007;566(1–3):226–30.PubMedCrossRef
30.
Zurück zum Zitat Gerber JG, Keller RT, Nies AS. Prostaglandins and renin release: the effect of PGI2, PGE2, and 13, 14-dihydro PGE2 on the baroreceptor mechanism of renin release in the dog. Circ Res. 1979;44(6):796–9.PubMed Gerber JG, Keller RT, Nies AS. Prostaglandins and renin release: the effect of PGI2, PGE2, and 13, 14-dihydro PGE2 on the baroreceptor mechanism of renin release in the dog. Circ Res. 1979;44(6):796–9.PubMed
31.
Zurück zum Zitat Jensen BL, Schmid C, Kurtz A. Prostaglandins stimulate renin secretion and renin mRNA in mouse renal juxtaglomerular cells. Am J Physiol. 1996;271(3 Pt 2):F659–69.PubMed Jensen BL, Schmid C, Kurtz A. Prostaglandins stimulate renin secretion and renin mRNA in mouse renal juxtaglomerular cells. Am J Physiol. 1996;271(3 Pt 2):F659–69.PubMed
32.
Zurück zum Zitat Kurtz A, Wagner C. Role of nitric oxide in the control of renin secretion. Am J Physiol. 1998;275(6 Pt 2):F849–62.PubMed Kurtz A, Wagner C. Role of nitric oxide in the control of renin secretion. Am J Physiol. 1998;275(6 Pt 2):F849–62.PubMed
33.
Zurück zum Zitat Malayan SA, Ramsay DJ, Keil LC, Reid IA. Effects of increases in plasma vasopressin concentration on plasma renin activity, blood pressure, heart rate, and plasma corticosteroid concentration in conscious dogs. Endocrinology. 1980;107(6):1899–904.PubMedCrossRef Malayan SA, Ramsay DJ, Keil LC, Reid IA. Effects of increases in plasma vasopressin concentration on plasma renin activity, blood pressure, heart rate, and plasma corticosteroid concentration in conscious dogs. Endocrinology. 1980;107(6):1899–904.PubMedCrossRef
34.
Zurück zum Zitat Merrill DC, Cowley AW Jr. Chronic effects of vasopressin on plasma renin activity in sodium-restricted dogs. Am J Physiol. 1986;250(3 Pt 2):F460–9.PubMed Merrill DC, Cowley AW Jr. Chronic effects of vasopressin on plasma renin activity in sodium-restricted dogs. Am J Physiol. 1986;250(3 Pt 2):F460–9.PubMed
35.
Zurück zum Zitat Schwartz J, Reid IA. Role of the vasoconstrictor and antidiuretic activities of vasopressin in inhibition of renin secretion in conscious dogs. Am J Physiol. 1986;250(1 Pt 2):F92–6.PubMed Schwartz J, Reid IA. Role of the vasoconstrictor and antidiuretic activities of vasopressin in inhibition of renin secretion in conscious dogs. Am J Physiol. 1986;250(1 Pt 2):F92–6.PubMed
36.
Zurück zum Zitat Arai Y, Fujimori A, Sasamata M, Miyata K. New topics in vasopressin receptors and approach to novel drugs: research and development of conivaptan hydrochloride (YM087), a drug for the treatment of hyponatremia. J Pharmacol Sci. 2009;109(1):53–9.PubMedCrossRef Arai Y, Fujimori A, Sasamata M, Miyata K. New topics in vasopressin receptors and approach to novel drugs: research and development of conivaptan hydrochloride (YM087), a drug for the treatment of hyponatremia. J Pharmacol Sci. 2009;109(1):53–9.PubMedCrossRef
37.
Zurück zum Zitat Zeltser D, Rosansky S, van Rensburg H, Verbalis JG, Smith N. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia. Am J Nephrol. 2007;27(5):447–57.PubMedCrossRef Zeltser D, Rosansky S, van Rensburg H, Verbalis JG, Smith N. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia. Am J Nephrol. 2007;27(5):447–57.PubMedCrossRef
38.
Zurück zum Zitat Yeates KE, Morton AR. Vasopressin antagonists: role in the management of hyponatremia. Am J Nephrol. 2006;26(4):348–55.PubMedCrossRef Yeates KE, Morton AR. Vasopressin antagonists: role in the management of hyponatremia. Am J Nephrol. 2006;26(4):348–55.PubMedCrossRef
39.
Zurück zum Zitat Ghali JK, Koren MJ, Taylor JR, Brooks-Asplund E, Fan K, Long WA, Smith N. Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. J Clin Endocrinol Metab. 2006;91(6):2145–52.PubMedCrossRef Ghali JK, Koren MJ, Taylor JR, Brooks-Asplund E, Fan K, Long WA, Smith N. Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. J Clin Endocrinol Metab. 2006;91(6):2145–52.PubMedCrossRef
40.
Zurück zum Zitat Decaux G, Soupart A, Vassart G. Non-peptide arginine-vasopressin antagonists: the vaptans. Lancet. 2008;371(9624):1624–32.PubMedCrossRef Decaux G, Soupart A, Vassart G. Non-peptide arginine-vasopressin antagonists: the vaptans. Lancet. 2008;371(9624):1624–32.PubMedCrossRef
41.
Zurück zum Zitat Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA. 2007;297(12):1319–31.PubMedCrossRef Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA. 2007;297(12):1319–31.PubMedCrossRef
42.
Zurück zum Zitat Gheorghiade M, Konstam MA, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA. 2007;297(12):1332–43.PubMedCrossRef Gheorghiade M, Konstam MA, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA. 2007;297(12):1332–43.PubMedCrossRef
43.
Zurück zum Zitat Ghali JK, Hamad B, Yasothan U, Kirkpatrick P. Tolvaptan. Nat Rev Drug Discov. 2009;8(8):611–2.PubMedCrossRef Ghali JK, Hamad B, Yasothan U, Kirkpatrick P. Tolvaptan. Nat Rev Drug Discov. 2009;8(8):611–2.PubMedCrossRef
44.
Zurück zum Zitat Goldsmith SR. Is there a cardiovascular rationale for the use of combined vasopressin V1a/V2 receptor antagonists? Am J Med. 2006;119(7 Suppl 1):S93–6.PubMedCrossRef Goldsmith SR. Is there a cardiovascular rationale for the use of combined vasopressin V1a/V2 receptor antagonists? Am J Med. 2006;119(7 Suppl 1):S93–6.PubMedCrossRef
Metadaten
Titel
The roles of V1a vasopressin receptors in blood pressure homeostasis: a review of studies on V1a receptor knockout mice
verfasst von
Yoko Fujiwara
Akito Tanoue
Gozoh Tsujimoto
Taka-aki Koshimizu
Publikationsdatum
01.02.2012
Verlag
Springer Japan
Erschienen in
Clinical and Experimental Nephrology / Ausgabe 1/2012
Print ISSN: 1342-1751
Elektronische ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-011-0497-y

Weitere Artikel der Ausgabe 1/2012

Clinical and Experimental Nephrology 1/2012 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.